Sunstone Life Science Ventures invests in Karolinska Development's portfolio company Forendo Pharma
STOCKHOLM – July 19, 2019. Karolinska Development's portfolio company Forendo Pharma announces today that Sunstone Life Science Ventures joins the existing international investor syndicate and has made a EUR 5 million investment in Forendo Pharma. Claus Andersson, General Partner from Sunstone, joins Forendo Pharma’s Board of Directors.
With the investment, Sunstone joins the existing international investor syndicate comprising Novo Seeds, Karolinska Development, Innovestor, Novartis Venture Fund, M Ventures and Vesalius Biocapital Partners.
The new financing will enable Forendo Pharma to progress its lead endometriosis program, FOR-6219, an HSD17B1 enzyme inhibitor, into the next phase of clinical studies after the successful completion of its Phase 1a study earlier this year.
Endometriosis is a chronic condition that affects many women of reproductive age and causes repeated pain symptoms, infertility and impaired quality of life. Currently available treatments for endometriosis have limitations in efficacy or cause harmful side effects, due to systemic estrogen depletion. The novel HSD17B1 inhibitor is the first concept aiming for a local effect in the endometriosis lesions.
“Forendo Pharma has shown reassuring progress the last year and it is very encouraging to see that they successfully continue to attract new capital", comments Viktor Drvota, CEO of Karolinska Development.
For further information, please contact :
Viktor Drvota, CEO, Karolinska Development AB
Phone: +46 73 982 52 02, e-mail: email@example.com
TO THE EDITORS
About Karolinska Development AB
Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients' lives while providing an attractive return on investment to shareholders.
Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around
scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.
Karolinska Development has established a portfolio of nine companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.
The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.
For more information, please visit www.karolinskadevelopment.com
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Abonnera på våra pressmeddelanden. Endast mejladress behövs och den används bara här. Du kan avanmäla dig när som helst.
Senaste pressmeddelandena från GlobeNewswire
ObsEva SA to Hold Conference Call to Discuss PRIMROSE 2 Trial Results on December 9, 20196.12.2019 22:30:00 CET | Press release
Geneva, Switzerland and Boston, MA –December 6, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that it will release results from the Phase 3 PRIMROSE 2 clinical trial of linzagolix for the treatment of heavy menstrual bleeding due to uterine fibroids, on Monday December 9, 2019. ObsEva management will host an investment community conference call at 8 a.m. Eastern Time, 2 p.m. Central European Time, Monday December 9, 2019, to discuss these results. Investors may participate by dialing (844) 419-1772 for U.S. callers or +1 (213) 660-0921 for international callers, and referring to conference ID 1764134. A webcast of the conference call can be accessed under the “Investors” section of ObsEva’s website www.obseva.com. About ObsEva ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics
OPENING OF A CALL FOR TENDER TO PROVIDE A CONTINUATION OR SALE PLAN IN THE FRAME OF REOGANIZATION PROCEEDINGS6.12.2019 17:45:00 CET | Press release
COMMUNIQUE DE PRESSE · COMMUNIQUE DE PRESSE · COMMUNIQUE DE PRESSE OPENING OF A CALL FOR TENDER TO PROVIDE A CONTINUATION OR SALE PLAN IN THE FRAME OF REOGANIZATION PROCEEDINGS The deadline for submission of all tenders is January 10th, 2020 before 04:00pm Paris and Boston, December 6th, 2019 – 05h45pm CET - Neovacs (Euronext Growth Paris : ALNEV) announces the launch of a call for tender opened from now until January 10th, 2020 before 4:00 pm, to provide a continuation plan through partners or investors (articles L.626-1 and L.626-3 of the French Commercial code) or a sale plan by one or more buyers (Articles L.642-1 et seq. of the French Commercial Code). Candidates are invited to submit their offer before January 10th, 2020 at 04:00pm at the following law office: SELARL 2M and associates, to Maître Carole Martinez, judicial administrator, 22 rue de l'Arcade 75008 Paris, France. Email: firstname.lastname@example.org Access to information for auditing the company (electronic data room), will b
Conditions for Riksbank Bid Procedures Sek Bonds6.12.2019 16:20:00 CET | Press release
Sveriges Riksbank Bid procedure details Government Bonds, 2019-12-12 Maturity date Loan ISIN code Coupon Volume, SEK million 2022-06-01 1054 SE0003784461 3.50 % 500 +/- 250 2029-11-12 1061 SE0011281922 0.75 % 500 +/- 250 Settlement date 2019-12-16 Bids have to be entered by 10.00 on DEC 12, 2019 Highest permitted bid volume: 500 SEK million in issue SGB 1054 and 500 SEK million in issue SGB 1061 Lowest permitted bid volume: 50 SEK million Bids only through counterparties approved by the Riksbank RESULT OF AUCTION WILL BE PUBLISHED NO LATER THAN 10.10 (CET) ON DEC 12, 2019. For more information, please contact: Trading desk at the Riksbank + 46 8 696 6970 General and special terms and conditions can be retrieved at http://www.riksbank.se
Result of AGM6.12.2019 16:15:00 CET | Press release
6 December 2019 Volta Finance Limited (VTA / VTAS) RESULTS OF THE THIRTEENTH ANNUAL GENERAL MEETING Volta Finance Limited announces that at the Thirteenth Annual General Meeting held earlier today all resolutions proposed were duly passed. Two of these resolutions were special resolutions. The full text of the resolutions can be found in the Notice of Meeting contained with the Annual Report and Accounts 2019, copies of which are available for viewing at on the Company’s website http://www.voltafinance.com The Board notes the votes against the resolutions to approve the re-election of the directors, Graham Harrison, Stephen Le Page, Paul Meader, Atosa Moini and Paul Varotsis, contained in resolutions 4 to 8 inclusive. The votes against each resolution equate to 37.05% of the total voted by proxy. The Board, through the Chair, AXA Investment Manager and the Company’s corporate broker, seeks to maintain an ongoing dialogue with major shareholders, including dissenting shareholders, and w
Beter Bed Holding announces sale and lease-back of the distribution centers in Hoogeveen and Nieuw-Vennep6.12.2019 15:00:00 CET | Press release
Highlights: Beter Beheer B.V., the wholly owned subsidiary of Beter Bed Holding, has entered into two separate sale-and-leaseback transactions for its properties in Hoogeveen and Nieuw-Vennep for a cash consideration of in total € 5.1 million. The total book profit on these transactions is circa € 1.6 million after tax. Together with the previously announced sale-and-leaseback transaction of the property in Uden (Linie 27), these transactions show that the Benelux operations of Beter Bed Holding will continue operating in its current logistical structure. These transactions contribute to the improvement of the net debt position of Beter Bed Holding, because the proceeds will be used to repay bank debt. Together with the divestment of Matratzen Concord that was completed on 2 December, these transactions are important steps for the transformation of Beter Bed Holding. John Kruijssen, CEO of Beter Bed Holding, comments: “With these sale-and-leaseback transactions and the divestment of Ma
Changes in ownership6.12.2019 14:43:00 CET | Press release
06 December 2019 Changes in ownership Redbrick Investments S.a.r.l. (Luxemburg) increased its stake in PJSC Acron to 62.65% from 62.48% by purchasing shares from JSC Agronova that decreased its stake to 0.15%. Media contacts: Sergey Dorofeev Anastasiya Gromova Tatiana Smirnova Public Relations Phone: +7 (495) 777-08-65 (ext. 5196) Investor contacts: Ilya Popov Investor Relations Phone: +7 (495) 745-77-45 (ext. 5252) Background Information Acron Group is a leading vertically integrated mineral fertiliser producer in Russia and globally, with chemical production facilities in Veliky Novgorod (Acron) and the Smolensk region (Dorogobuzh). The Group owns and operates a phosphate mine in Murmansk region (North-Western Phosphorous Company, NWPC) and is implementing a potash development project in Perm Krai (Verkhnekamsk Potash Company, VPC). It owns transportation and logistics infrastructure, including three Baltic port terminals and distribution networks in Russia and China. Acron’s subsidi